Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKarim FizaziDVDonald Charles VileZCZheng Hong Chen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fizazi et al. (2024) studied this question.

synapsesocial.com/papers/68e67065b6db6435875faf70https://doi.org/10.1200/jco.2024.42.16_suppl.tps5114
View Full Paper
Ask AI
Bookmark
Share